This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Rosen Law Firm Announces Investigation Of Shareholder Securities Claims Against Prosensa Holding NV – RNA

The Rosen Law Firm, P.A. announces that it has commenced an investigation into allegations that Prosensa Holding NV (NASDAQ:RNA) may have violated federal securities laws by issuing false and misleading statements to investors about its business and financial condition.

Prosensa Holding NV is a biotechnology company that develops ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The Company focuses on neuromuscular and neurodegenerative disorders, including Duchenne muscular dystrophy (“DMD”), myotonic dystrophy and Huntington's disease. The Company’s lead product candidate is drisapersen, which aims to treat DMD.

The investigation relates to allegations that the Company’s Registration Statement and Prospectus issued in connection with its initial public offering on June 28, 2013 were materially false and misleading. Specifically, the investigation focuses on allegations that the Prosensa misrepresented or failed to disclose material facts concerning the efficacy of drisapersen and its prospects for marketing and regulatory approval.

The Rosen Law Firm is preparing a securities class action lawsuit on behalf of Prosensa investors. If you purchased Prosensa stock please visit the website at http:/rosenlegal.com to join the class action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs